MATRINE

Possibly Marketed Outside US

First approved in 2018

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H24N2O
Molecular Weight	248.3639
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12CCCN3CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]

InChI

InChIKey=ZSBXGIUJOOQZMP-JLNYLFASSA-N

InChI=1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C15H24N2O
Molecular Weight	248.3639
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26862304 | https://www.ncbi.nlm.nih.gov/pubmed/28190318 | https://www.ncbi.nlm.nih.gov/pubmed/10232067 | https://www.ncbi.nlm.nih.gov/pubmed/14969841 | https://www.ncbi.nlm.nih.gov/pubmed/16252735

Matrine is an active alkaloid, extracted from a traditional Chinese herbs of the Sophora family. Matrine has been reported for its anti-inflammatory and neuroprotective effects. It was demonstrated that the antinociceptive effects of ( )-matrine was mediated by mu- and kappa-opioid receptors. It could dose-dependently restore the balance of Th17/Treg cytokines and attenuate the cognitive impairment in Alzheimer's disease rats. Sophora flavescens and its bioactive compound, matrine alleviated caffeine-induced hyperactivity and promoted non-rapid eye movement sleep by activating ventrolateral preoptic nucleus neurons and modulating serotonergic transmission. Clinical trial results indicate, that intramuscular matrine may be an economical, efficacious, safe drug for the treatment of chronic hepatitis B. Matrine injection may be used to protect the liver function for patients with primary hepatic carcinoma after trans-artery chemo-embolization (TAE), to relieve the liver cells damage, and to improve the tolerance of TAE, so as to perform the next TAE in time.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Kappa opioid receptor 115 Target ID: CHEMBL4329 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10232067	Agonist 2752
Mu opioid receptor 231 Target ID: CHEMBL2858 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10232067	Agonist 2752
Apoptosis 156 Target ID: WP254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20818811 \| https://www.ncbi.nlm.nih.gov/pubmed/25269486	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Silicosis 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23257008	Palliative	Phase II 1147	Unknown Approved Use Unknown
Primary hepatic carcinoma 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16252735 https://www.ncbi.nlm.nih.gov/pubmed/20818811	Secondary	Phase II 1147	Unknown Approved Use Unknown
Chronic hepatitis B 16 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14969841	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
603.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2384.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1207.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
6375 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
20316 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
13047 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19726245/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
150 mg 1 times / day multiple, intramuscular Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16252735	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16252735	Sources: https://pubmed.ncbi.nlm.nih.gov/16252735

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 779 OCT3 159 P-gp 1741 OCT1 620	rUGT 1 rCYP 3

Drug as perpetrator

Target	Modality	Activity
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24291757/	no [IC50 >100 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24291757/	no [Inhibition 100 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24380838/	no [Inhibition 100 uM]
OCT3 161	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24291757/	no [Inhibition 6000 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32655683/	weak [Inhibition 100 uM]
MRP1 232	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/29130495/	yes
P-gp 1932	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/29130495/ \| https://pubmed.ncbi.nlm.nih.gov/31871929/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
rCYP 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/20034755/	no
rUGT 1	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/20034755/	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/20535583/

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00386L	https://www.1pchem.com/search?query=1P00386L
A2B Chem	AB49773	http://a2bchem.com/prod/AB49773
AK Scientific	O723	https://aksci.com/item_detail.php?cat=O723
Ambeed	A145595	http://www.ambeed.com/search/Search.html?keyword=A145595
Angene	AGN-PC-0SBNYH	http://www.angenechemical.com/productshow/AGN-PC-0SBNYH.html
ApexBio Technology	A3583	https://www.apexbt.com/catalogsearch/result/?q=A3583
AstaTech	44284	http://astatechinc.com/CPSResult.php?CRNO=44284
Biopurify Phytochemicals	BP0928	https://www.phytopurify.com/search.do?a=s&searchtype=3&psize=10&q=BP0928&searchhtmp=simplesearch&t=1
BLD Pharm	BD8176	http://www.bldpharm.com/search/Search.html?keyword=BD8176
BOC Sciences	519-02-8	http://www.bocsci.com/description.asp?cas=519-02-8
Capot Chemical	35669	https://www.capotchem.com/search.do?q=35669
Chem-Impex International	32545	http://www.chemimpex.com/category/search/32545/2?filter=&search=32545&type=q&keywordoption=ANY&cid=2&fltrdesc=
Chem Scene	CS-1601	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1601
Chem4Pharma	C4PN25	https://www.chem4pharma.com/product-page/C4PN25
ChemDiv	3886-1221	http://chemistryondemand.com:8080/eShop/search_results.jsp?idnumber=3886-1221
ChemShuttle	151630	https://www.chemshuttle.com/catalogsearch/result/?q=151630
eMolecules	1936111	https://orderbb.emolecules.com/search/#?query=1936111
eMolecules	195180068	https://orderbb.emolecules.com/search/#?query=195180068
eMolecules	298143212	https://orderbb.emolecules.com/search/#?query=298143212
eMolecules	303891852	https://orderbb.emolecules.com/search/#?query=303891852
eNovation Chemicals	D491463	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D491463&searchbtn.x=0&searchbtn.y=0
Fluorochem	464368	http://www.fluorochem.co.uk/Products/Product?code=464368
Frontier Scientific Services	501002325	http://orders.frontierssi.com/fssionline32/public/product.aspx?cat=501002325&type=hts
Indofine	06-019	https://indofinechemical.com/details.aspx?Sku=06-019
KeyOrganics	KS-5203	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=KS-5203
mcule	MCULE-2562302442	https://mcule.com/MCULE-2562302442/
mcule	MCULE-2757887204	https://mcule.com/MCULE-2757887204/
mcule	MCULE-3153605825	https://mcule.com/MCULE-3153605825/
MedChem Express	HY-N0164	https://www.medchemexpress.com/search.html?q=HY-N0164&ft=&fa=&fp=
Molnova	M14816	https://www.molnova.com/en/serch-list.html?keywords=M14816
MolPort	MolPort-002-517-366	https://www.molport.com/shop/molecule-link/MolPort-002-517-366
MolPort	MolPort-044-724-732	https://www.molport.com/shop/molecule-link/MolPort-044-724-732
PI Chemicals	PI-28600	http://www.pipharm.com/catalog_products/PI-28600.html
Princeton BioMolecular Research	PBMR232774	http://www.princetonbio.com/order_online?common_id=PBMR232774
Ryan Scientific	Tetrahydropalmatine	https://ryansci.com/products?q=Tetrahydropalmatine&list_q=&search_type=exact
Selleck Chemicals	S2322	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2322
ShangHai Biochempartner	BCP08193	http://www.biochempartner.com/search_BCP08193
TargetMol	BBP60007	https://www.targetmol.com/search?keyword=BBP60007
TargetMol	T2870	https://www.targetmol.com/search?keyword=T2870
Tetrahedron	TS27812	http://www.thsci.com/search.do?q=TS27812

PubMed

Title	Date	PubMed
Simultaneous determination and pharmacokinetic study of oxymatrine and matrine in beagle dog plasma after oral administration of Kushen formula granule, oxymatrine and matrine by LC-MS/MS.	2007-08	17431934
Matrine induces apoptosis in angiotensin II-stimulated hyperplasia of cardiac fibroblasts: effects on Bcl-2/Bax expression and caspase-3 activation.	2007-07	17577309
Simultaneous quantification of oxysophocarpine and its active metabolite sophocarpine in rat plasma by liquid chromatography/mass spectrometry for a pharmacokinetic study.	2007-07	17428011
Effect of matrine on HeLa cell adhesion and migration.	2007-06-01	17343841
Effect of matrine on the expression of substance P receptor and inflammatory cytokines production in human skin keratinocytes and fibroblasts.	2007-06	17466915
LC-MS characterization of efficacy substances in serum of experimental animals treated with Sophora flavescens extracts.	2007-06	17370298
NACE-ESI-MS combined with on-line concentration for high-sensitivity analysis of quinolizidine alkaloids.	2007-05	17427256
[Effects of baicalin and other Chinese herbal monomer on androgen receptor mRNA expression in SZ95 sebocytes].	2007-04	17536261
Supercritical fluid extraction of quinolizidine alkaloids from Sophora flavescens Ait. and purification by high-speed counter-current chromatography.	2007-03-23	17289059
Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells.	2007-03-22	17291488
[Effects of matrine, oxymatrine and resveratrol on HERG channel expression].	2007-02	17518040
[Determination of matrine, sophoridine and oxymatrine in Compound Kushen Injection by HPLC].	2007-02	17432143
[Matrine-induced gamma-globin synthesis in K562 cells].	2007-02	17355941
Protective effect of glycyrrhizin and matrine on acute vanishing bile duct syndrome induced by alpha-naphthylisothiocyanate in rats.	2007-02	17300710
Protective effect of glycyrrhizin, glycyrrhetic acid and matrine on acute cholestasis induced by alpha-naphthyl isothiocyanate in rats.	2007-02	17206559
Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family.	2007-01-18	17134813
[HPCE determination of matrine in matrine liposome].	2007-01	17539315
[Optimization of preparation for matrine-loaded magnetic chitosan microspheres].	2007-01	17539310
[Inducement effect of matrine on phenotype changes of rat hepatic oval cells].	2006-12	17166375
A rapid reversed phase high-performance liquid chromatographic method for determination of sophoridine in rat plasma and its application to pharmacokinetics studies.	2006-10-20	16781900
[An approach to the mechanism of matrine and albendazole against Echinococcus multilocularis infection in mice].	2006-10	17361819
[Clinical observation on treatment of 75 mid-late stage cancer patients with yanshu Injection].	2006-08	16970087
[Inhibition of extracts from 17 Chinese herbs on periodontal pathogenic microbes].	2006-08	16955176
[The effects of matrine on cell proliferation and telomerase activity in retinoblastoma cells in vitro].	2006-07	17081416
[Effects of matrine on proliferation and apoptosis of human renal cell carcinoma cell line GRC-1].	2006-07	16834977
Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry.	2006-06-07	16500065
Matrine-induced apoptosis in leukemia U937 cells: involvement of caspases activation and MAPK-independent pathways.	2006-05	16773533
Determination of quinolizidine alkaloids in Sophora flavescens and its preparation using capillary electrophoresis.	2006-05	16167304
[Constituents in the alkaloid fraction of Kushen decoction].	2006-04	16780157
Antiviral effects of sophoridine against coxsackievirus B3 and its pharmacokinetics in rats.	2006-03-20	16309710
[Inhibition of invasiveness and expression of heparanase-mRNA in human malignant melanoma cell line A375 by matrine].	2006-03	16850724
Effect of matrine and carvedilol on collagen and MMPs activity of hypertrophy myocardium induced by pressure overload.	2006-03	16502514
Matrine improves 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice.	2006-03	16332442
Using LC/MS/MS to determine matrine, oxymatrine, ferulic acid, mangiferin, and glycyrrhizin in the Chinese medicinal preparations Shiau-feng-saan and Dang-guei-nian-tong-tang.	2006-02-13	16181760
[Experimental study on effect of matrine in alleviating renal tubulointerstitial fibrosis in unilateral ureteral obstruction model].	2006-02	16548356
[Study of matrine's use on the reversion of obtained multi-drug resistance of mice S80 tumour cell].	2006-01	16722318
[Effects of Matrine Injection on T-lymphocyte subsets of patients with malignant tumor after gamma knife radiosurgery].	2006-01	16409978
Molecular mechanism of matrine-induced apoptosis in leukemia K562 cells.	2006	17163597
[The interference in correlated molecular mechanism obtained multi-drug resistance of mouse S180's tumour cell for different alkaloid].	2005-12	16499024
[Study on electrochemical kinetics of matrine and sophoridine in a physiological medium].	2005-12	16499022
[Effect of matrine on regulating renal tubulointerstitial expression of MMP-3, TIMP-1 and FN].	2005-11	16334561
Physicochemical characterization of the Strychnos alkaloids by capillary zone electrophoresis.	2005-11	16317898
Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats.	2005-10-14	16273603
[Clinical study of matrine injection on preventing liver function damage of anti-tumor drugs during chemotherapy of breast cancer].	2005-08	16379429
[HPLC-electrospray ionization ion trap tandem mass spectrometry analysis of oxymatrine and its metabolites in rat urine].	2005-08	16268510
[Clinical study on effect of matrine injection to protect the liver function for patients with primary hepatic carcinoma after trans-artery chemo-embolization (TAE)].	2005-07	16252735
[Inhibition of tumor growth in tumor-bearing mice treated with matrine].	2005-06	16117895
[Apoptosis of human oral epidermoid carcinoma KB cells and multidrug resistant KBv200 cells induced by matrine].	2005-06	16078472
[Study on direct electrochemical behaviors and the electroanalytical method of matrine type alkaloids at glassy carbon electrode].	2005-05	16075717
[Renoprotective effects of matrine on experimental glomerulosclerosis in rats].	2004-10	16221339

Patents

Sample Use Guides

In Vivo Use Guide

100 mg daily for 90 days

Route of Administration: Intramuscular

In Vitro Use Guide

72 h of matrine (50 - 800 mg/L) exposure significantly suppresses Hep3B cells growth in a concentration-dependent manner (P<0.01), the 50 percent inhibitory concentration (IC50) was 312.53 mg/L.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:25:32 GMT 2025` Edited by `admin` on `Mon Mar 31 22:25:32 GMT 2025`
Record UNII	N390W430AC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VEGARD

Preferred Name

English

MATRINE

Official Name

English

NSC-318810

Code

English

Matrine [WHO-DD]

Common Name

English

MATRIDIN-15-ONE

Common Name

English

(+)-MATRINE

Common Name

English

.ALPHA.-MATRINE

Common Name

English

MATRINE [MI]

Common Name

English

1H,5H,10H-DIPYRIDO(2,1-F:3',2',1'-IJ)(1,6)NAPHTHYRIDIN-10-ONE, DODECAHYDRO-, (7AS,13AR,13BR,13CS)-

Systematic Name

English

NSC-146051

Code

English

Code System Code Type Description

WIKIPEDIA

Matrine